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Abstract
We have recently shown that the hormonal form of vitamin D3, 1,25(OH)2-vitamin D3 (1,25(OH)2D3), stimulates the
enzymatic activity of the non-receptor protein tyrosine kinase c-Src in skeletal muscle cells. In this study we show that
intracellular and extracellular Ca2 chelation with BAPTA and EGTA, respectively, blocked hormone stimulation of c-Src
activity/dephosphorylation, indicating that the calcium messenger system is an upstream activator of c-Src. Tyrosine
phosphorylation and stimulation of the growth-related mitogen-activated protein kinase (MAPK) by 1,25(OH)2D3 was
shown to be dependent on activation of c-Src, since pretreatment with the c-Src specific inhibitor PP1 or muscle cell
transfection with an antisense oligodeoxynucleotide directed against c-Src mRNA markedly reduced hormone stimulation of
MAPK phosphorylation. Evidence was obtained indicating that MAPK is then translocated to the cell nucleus in active
phosphorylated form and induces the expression of c-myc oncoprotein, as the MAPK kinase (MEK) inhibitor PD98059
abolished stimulation of c-myc synthesis by 1,25(OH)2D3. In addition, the hormone rapidly stimulated tyrosine
phosphorylation of c-myc. In cells pretreated with PP1 (4-amino-5-(4-methylphenyl)-7-(t-butyl)pyrazolo-D3,4-pyrimidine),
the 1,25(OH)2D3-induced increase in tyrosine phosphorylation of c-myc was suppressed. Taken together, these results
demonstrate that 1,25(OH)2D3 stimulates proliferation-associated signalling pathways in skeletal muscle cells and implicate
c-Src kinase as mediator of this response. ß 2001 Elsevier Science B.V. All rights reserved.
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1. Introduction
1,25-Dihydroxyvitamin D3 (1,25(OH)2D3), the ma-
jor biologically active metabolite of vitamin D3, has a
well-recognized role in the regulation of mineral me-
tabolism [1,2] and also in£uences cellular prolifera-
tion and di¡erentiation [3,4]. As for sex steroid hor-
mones it was thought that all the e¡ects of
1,25(OH)2D3 were mediated by binding to a nuclear
receptor (vitamin D receptor; VDR) [5] which in turn
interacts with speci¢c response elements of a wide
number of genes [6]. However, 1,25(OH)2D3 also ex-
erts rapid actions (seconds to minutes) on the plasma
membrane, activating several signalling cascades, an
observation which was initially reported for the duo-
denum [7] and promptly extended to several other
classical as well as non-classical target tissues [8^13].
The initiation of the fast 1,25(OH)2D3 signal may
involve binding to a novel membrane receptor, whose
existence received ¢rst experimental support in enter-
ocytes [14] and more recently in chondrocytes [15].
Diverse transmembrane signalling systems mediate
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the non-genomic actions of 1,25(OH)2D3 in muscle
cells, resulting in G protein-mediated modulation of
adenylyl cyclase and phospholipases C, D and A2 and
activation of protein kinases A (PKA) and C (PKC),
which in turn regulate the activity of voltage-depen-
dent Ca2 channels (VDCC) [16^21]. In addition, the
hormone promotes Ca2 mobilization from intracel-
lular stores and modulates the Ca2 release-activa-
ted Ca2 in£ux (SOC) pathway as part of the
1,25(OH)2D3-induced Ca2 entry across the plasma
membrane of skeletal muscle cells [22,23]. Recent evi-
dence indicates that 1,25(OH)2D3 rapidly stimulates
the enzymatic activity of c-Src tyrosine kinase in em-
bryonic skeletal muscle cells [24], rat colonocytes [25]
and human keratinocytes [26]. In intestinal and skin
cells the hormone induces c-Src-mediated tyrosine
phosphorylation of PLCQ and the adaptor protein
Shc, respectively [23]. Non-receptor tyrosine kinases
are believed to act as signal transduction molecules
which link up the signals originating from receptors
with appropriate downstream e¡ector pathways, such
as the mitogen-activated protein (MAP) kinase
(MAPK) pathway [27,28]. Congruent with this con-
cept, it has been shown that 1,25(OH)2D3 is able to
stimulate the MAP kinase signalling cascade in pro-
myelocytic NB4 leukaemia cells [29], chick entero-
cytes [30] and skeletal muscle cells [31] as evidenced
by hormone-dependent increases in tyrosine phos-
phorylation and enzymatic activity of MAPK.
The signi¢cance of non-genomic signalling through
c-Src stimulation is largely unknown. There is some
evidence that tyrosine phosphorylation events initi-
ated by c-Src activation may play an important
role in the modulation of cellular growth by
1,25(OH)2D3 [31,32]. In view of the mitogenic role
of 1,25(OH)2D3 in embryonic skeletal muscle cells
[33^35], in the present study we have investigated
whether c-Src is required for 1,25(OH)2-vitamin D3
signalling to the nucleus in these cells.
2. Material and methods
2.1. Chemicals
1,25(OH)2D3 was supplied by Dr. Heinrich Bach-
mann (Ho¡mann-La Roche, Basel, Switzerland).
Myelin basic protein, enolase, compound PD98059,
protein A-Sepharose, Dulbecco’s modi¢ed Eagle’s
medium (DMEM) and fetal bovine serum were
from Sigma (St. Louis, MO, USA). Lipofectin was
from Gibco BRL (Gaithersburg, MD, USA). Rabbit
polyclonal anti-phosphotyrosine antibody was ob-
tained from Upstate Biotechnology (Lake Placid,
NY, USA). Anti-active MAP kinase antibody (reac-
tive against p42 and p44 isoforms) and anti-Src anti-
body were from Promega (Madison, WI, USA).
Anti-c-myc antibody was purchased from Oncogene
Research Products (Cambridge, MA, USA). Second-
ary antibody goat anti-rabbit horse radish peroxi-
dase-conjugated IgG and the Super Signal CL-HRP
substrate system for enhanced chemiluminescence
(ECL) were obtained from Amersham (Arlington
Heights, IL, USA). [Q-32P]ATP (3000 Ci/mmol) was
from New England Nuclear (Chicago, IL, USA).
Sense and antisense oligodeoxynucleotides were syn-
thesized by the DNAgency (Malvern, PA, USA). All
other reagents were of analytical grade.
2.2. Cell culture
Chick skeletal muscle cells (myoblasts) were ob-
tained from 13-day-old chick embryo breast muscles
by stirring in Earl’s balanced salt solution (SSBE)
containing 0.1% trypsin during 30 min essentially as
previously described [36]. The freed cells were col-
lected by centrifugation and the pellet was resus-
pended in DMEM supplemented with 10% fetal bo-
vine serum and antibiotic^antimycotic solution. The
suspension was dispersed by pipetting, ¢ltered
through nylon mesh and preplated on gelatin-coated
petri dishes to remove contaminating ¢broblasts. The
unadsorbed cells were seeded at an appropriate den-
sity (120 000 cells/cm2) in petri dishes (80 mm diam-
eter) and cultured at 37‡C under a humidi¢ed atmos-
phere (air/5% CO2). Cells were allowed to grow until
con£uence (4^5 days after plating) before use. Under
these conditions, myoblasts proliferate within the ¢rst
48 h and at day 4 become di¡erentiated into myo-
tubes expressing both biochemical and morphological
characteristics of adult skeletal muscle ¢bres [37].
2.3. Isolation of cell nuclei
Cells were resuspended in 10 mM Tris^HCl pH
7.4, 1.6 M sucrose, 0.1 mM Na3VO4, 5 mM DTT
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and 0.3 mM phenylmethylsulphonyl £uoride (PMSF)
and then sonicated for 15 s. The nuclei were obtained
by layering the lysed cell suspension on a sucrose
cushion (2 M) and subjecting the samples to centri-
fugation at 4000Ug at 4‡C, for 15 min. The nuclear
pellets were washed twice in lysis bu¡er. Microscopic
examination of the pellet after trypan blue staining
revealed a high yield of puri¢ed nuclei. Nuclei were
immediately frozen and stored at 370‡C until used
in the assays. Measurement of cytosolic glucose-6-
phosphate dehydrogenase in the nuclear and super-
natant fractions [38] showed no detectable enzymatic
activity associated to the nuclei (data not shown).
2.4. Immunoprecipitation
After treatment, muscle cells were lysed (30 min at
4‡C) in 50 mM Tris^HCl, pH 7.4, 150 mM NaCl,
2 mM EGTA, 25 mM NaF, 0.2 mM sodium ortho-
vanadate, 1 mM PMSF, 2 Wg/ml leupeptin, 2 Wg/ml
pepstatin, 2 Wg/ml aprotinin, 0.25% sodium deoxy-
cholate and 1% NP40. Insoluble material was pel-
leted in a microcentrifuge at 14 000 rpm for 10
min. The protein content of the clear lysates was
determined according to Lowry [39]. Aliquots (500^
700 Wg protein) were incubated overnight at 4‡C with
anti-Src or anti-c-myc antibodies, followed by precip-
itation of the complexes with protein A conjugated
with Sepharose. The immune complexes were washed
¢ve times with cold immunoprecipitation bu¡er (10
mM Tris^HCl, pH 7.4, 150 mM NaCl, 1 mM
EGTA, 1 mM EDTA, 0.2 mM PMSF, 0.2 mM so-
dium orthovanadate, 1% Triton X-100 and 1%
NP40).
2.5. SDS^PAGE and immunoblotting
Immunoprecipitated proteins (or lysate proteins)
dissolved in Laemmli sample bu¡er were separated
on SDS^polyacrylamide (8%) gels [40], and electro-
transferred to polyvinylidene di£uoride (PVDF)
membranes. The membranes were blocked for 1 h
at room temperature in TBST (50 mM Tris^HCl,
pH 7.4, 200 mM NaCl, 1% Tween 20) containing
1% dry milk. For the detection of proteins, mem-
branes were subjected to immunoblotting using a
rabbit anti-phosphotyrosine, anti-active MAP kinase
(p42 and p44 isoforms) or anti c-myc antibodies.
Next, the membranes were washed three times in
TBST, incubated with a 1/10 000 dilution of peroxi-
dase-conjugated anti-rabbit secondary antibody for
1 h at room temperature and washed three additional
times with TBST. The membranes were then visual-
ized using an enhanced chemiluminescent technique
(ECL, Amersham), according to the manufacturer’s
instructions. Images were obtained with a model GS-
700 Imaging Densitometer from Bio-Rad (Hercules,
CA, USA) by scanning at 600 dpi and printing at the
same resolution. Bands were quanti¢ed using the
Molecular Analyst program (Bio-Rad).
2.6. Measurement of Src kinase activity
Cell lysates were prepared followed by immuno-
precipitation of Src as described above. After three
washes with immunoprecipitation bu¡er and two
washes with kinase bu¡er (50 mM Tris^HCl, pH
7.4, 5 mM MgCl2, 1 mM dithiothreitol, 0.1 mM
sodium orthovanadate), the immune complexes
were incubated at 30‡C for 10 min in kinase bu¡er
(30 Wl/sample) containing enolase as an exogenous
substrate for Src (2.5 Wg/assay), 50 WM ATP and
[Q-32P]ATP (2 WCi/assay). To terminate the reaction,
the phosphorylated product was separated from free
isotope on ion-exchange phosphocellulose ¢lters
(Whatman P-81). Papers were immersed immediately
into ice-cold 75 mM H3PO4, washed (1U5 min,
3U20 min) and counted in a scintillation counter.
2.7. Measurement of MAP kinase activity
Lysates were prepared followed by immunopreci-
pitation of MAP kinase (p42 and p44) as described
above. After three washes with immunoprecipitation
bu¡er and two washes with kinase bu¡er (10 mM
Tris^HCl, pH 7.2, 5 mM MgCl2, 1 mM MnCl2,
1 mM dithiothreitol, 0.1 mM sodium orthovanadate,
1 mM phenylmethylsulphonyl £uoride, 20 Wg/ml leu-
peptin, 20 Wg/ml aprotinin and 20 Wg/ml pepstatin),
the immune complexes were incubated at 37‡C for 10
min in kinase bu¡er (50 Wl/sample) containing myelin
basic protein as an exogenous substrate for MAPK
(20 Wg/assay), 25 WM ATP and [Q-32P]ATP (2.5 WCi/
assay). To terminate the reaction, the phosphorylat-
ed product was separated from free isotope on ion-
exchange phosphocellulose ¢lters (Whatman P-81).
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Papers were immersed immediately into ice-cold 75
mM H3PO4, washed (1U5 min, 3U20 min) and
counted in a scintillation counter.
2.8. Cell transfection
Transfection with oligodeoxynucleotides (ODNs)
using Lipofectin was performed according to the
manufacturer’s instructions. As in previous studies
[41,42], ODNs were incubated with Lipofectin in
DME for 15 min at room temperature. Plates of
subcon£uent cells were washed to remove serum be-
fore addition of ODN^Lipofectin mixtures and incu-
bation was performed for 12 h at 37‡C. The ODN
solution was removed, DME was added and the
plates were placed in a metabolic incubator for an
additional period of 36 h. Control treatments in-
cluded DME or Lipofectin only. Dose^ and time^
response curves for Lipofectin and ODN were pre-
viously optimized (not shown).
The following ODN sequences with phosphoro-
thioate linkages throughout the entire molecule
were used: anti-c-Src, 5P-CACCACCATGGGGAG-
CAGCA-3P (antisense against the 95^114 nucleotide
sequence containing the AUG region from Gallus
gallus c-Src mRNA); sense-c-Src, 5P-TGCTGCTCC-
CCATGGTGGTG-3P.
2.9. Statistical analysis
Statistical signi¢cance of the data was evaluated
using Student’s t-test [43] and probability values be-
low 0.05 (P6 0.05) were considered signi¢cant. Re-
sults are expressed as means þ standard deviation
(S.D.) from the indicated set of experiments.
3. Results and discussion
There is increasing evidence suggesting that Src
tyrosine kinases have a pivotal role in the regulation
of various cellular processes [44]. Members of this
family are thought to be involved in signal transduc-
tion mechanisms linked to the MAPK cascade
underlying the regulation of cell proliferation and
di¡erentiation by agonists of receptor tyrosine ki-
nases or heterotrimeric G protein-coupled receptors
[45]. We have recently reported that the steroid hor-
mone 1,25(OH)2D3 stimulates, within 1^15 min,
c-Src kinase activity in skeletal muscle cells by a
mechanism that is sensitive to genistein and herbimy-
cin and implies c-Src dephosphorylation [24]. To fur-
ther explore hormone signal transduction in muscle
cells, we initially determined whether Ca2 is an up-
stream mediator of 1,25(OH)2D3-induced c-Src acti-
vation. As shown in Table 1, using a c-Src speci¢c
monoclonal antibody and enolase as c-Src substrate,
we found, in agreement with previous observations
[24], that 5 min treatment with 1 nM 1,25(OH)2D3
(hormone concentration which elicits a maximal re-
sponse in muscle intracellular calcium levels [46,47])
caused a 12-fold increase in c-Src kinase activity in
muscle cells. Membrane depolarization with high
KCl (75 mM) elicited only a 1-fold activation of c-
Src, an e¡ect that relies primarily on calcium in£ux
from the outside. In muscle cells that have been
loaded with the intracellular Ca2 chelator BAPTA
(5 WM), 90% inhibition of 1,25(OH)2D3-induced c-
Src activity was observed. In avian skeletal muscle
cells 1,25(OH)2D3 stimulates c-Src kinase activity, at
least in part, by altering the tyrosine phosphorylation
state of the enzyme [24] and in rat colonocytes
1,25(OH)2D3 activates Src by both phosphoryla-
tion-dependent and phosphorylation-independent
mechanisms [25]. It is well established that phosphor-
ylation of a conserved tyrosine residue (Y527) at the
carboxy-terminal tail of the Src molecule negatively
modulates its kinase activity by a mechanism which
Table 1
1,25(OH)2D3 stimulation of c-Src kinase activity is suppressed
by intracellular calcium chelation with BAPTA
c-Src activity (cpmUmg prot.)
Control 60.26 þ 4.6
1,25(OH)2D3 785.10 þ 55.6*
KCl (75 mM) 124.64 þ 8.7**
BAPTA 80.06 þ 5.6
BAPTA+1,25(OH)2D3 102.85 þ 7.4
Skeletal muscle cells were incubated with 1,25(OH)2D3 (1 nM)
in the absence or presence of the intracellular Ca2 chelator
BAPTA (5 WM), KCl (75 mM) or vehicle ethanol (6 0.01%)
for 5 min, and then lysed. Cell lysates were precipitated with
anti-c-Src antibody and the tyrosine kinase activity in the pre-
cipitate was assayed using [Q-32P]ATP and enolase as the exoge-
nous substrate. The radioactive product was separated on phos-
phocellulose and its activity counted in a scintillation counter.
Results are the average of three independent experiments per-
formed in triplicate þ S.D. *P6 0.001, **P6 0.005.
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apparently implies intramolecular interaction of the
carboxy-terminal phosphorylated tyrosine with the
SH2 domain of Src [48,49]. We then investigated
the e¡ects of BAPTA and EGTA on hormone-in-
duced changes in tyrosine phosphorylation of c-Src,
by immunoprecipitation of c-Src followed by immu-
noblotting with anti-phosphotyrosine antibody. As
shown in Fig. 1, the hormone e¡ectively caused a
decrease in the tyrosine phosphorylation status of
c-Src (360% with respect to control), thus paralleling
1,25(OH)2D3 stimulation of Src kinase-mediated
enolase phosphorylation. In muscle cells loaded
with the intracellular Ca2 chelator BAPTA (5
WM), the reduction of c-Src dephosphorylation in-
duced by the hormone was signi¢cantly attenuated
(330% with respect to control), while pretreatment
with EGTA (0.5 mM) abolished the e¡ects of
1,25(OH)2D3. These results suggest that both Ca2
release from internal stores and Ca2 in£ux from the
external milieu contribute to c-Src activation by
1,25(OH)2D3 in skeletal muscle cells. In agreement
with this interpretation, we have previously shown
that the hormone elicits a rapid IP3-mediated mobi-
lization of Ca2 from a thapsigargin-sensitive store
[22], and a sustained phase due to Ca2 in£ux
through VDCC and SOC channels [22,23]. The less
marked e¡ects of KCl than 1,25(OH)2D3 to stimu-
late Src activity mentioned above (Table 1) may be
explained by the fact that the former treatment only
activates the VDCC Ca2 pathway. Altogether, these
results suggest that the mechanism by which the
1,25(OH)2D3-induced Ca2 signal translates into an
increase of c-Src may involve stimulation of a Ca2-
dependent tyrosine phosphatase. In other cell types
inhibition of calcium in£ux has been shown to pre-
vent tyrosine phosphorylation of p60 c-Src kinase
[45,50].
MAPK or extracellular signal-regulated kinase
(ERK) consists of 42 and 44 kDa isoforms, and re-
quires both tyrosine and threonine phosphorylation
for activation [51,52]. To evaluate whether the cyto-
solic tyrosine kinase c-Src is part of the 1,25(OH)2D3
signalling mechanism involving MAPK in skeletal
muscle cells [29], we investigated the e¡ect of the c-
Src family tyrosine kinase-selective inhibitor PP1 [53]
on MAPK phosphorylation induced by the hormone.
To that end, cells pretreated with 10 WM PP1, fol-
lowed by exposure to 1 nM 1,25(OH)2D3 for 1 min,
Fig. 1. E¡ects of BAPTA and EGTA on 1,25(OH)2D3-induced
c-Src dephosphorylation. Chick skeletal muscle cells were incu-
bated with 1,25(OH)2D3 (1 nM) in the presence or absence of
the intracellular Ca2 chelator BAPTA (5 WM), EGTA (0.5
mM) or vehicle ethanol (6 0.01%) for 5 min, and then lysed.
Cell lysates were precipitated with anti-c-Src antibody followed
by Western blotting with anti-phosphotyrosine antibody as de-
scribed in Section 2. (A) Representative immunoblot. (B) Quan-
ti¢cation by scanning volumetric densitometry of blots from
three independent experiments; averages þ S.D. are given.
*P6 0.05, with respect to the control. (C) The blotted mem-
brane shown in panel A was re-probed with anti-Src antibody
as indicated in Section 2 in order to evaluate equivalence of Src
kinase content among the di¡erent experimental conditions.
Table 2
1,25(OH)2D3 stimulation of MAPK activity is suppressed by
the c-Src inhibitor PP1
MAPK activity (% above control)
Control 100 þ 2.7
1,25(OH)2D3 280 þ 8.5*
PP1 100 þ 3.9
PP1+1,25(OH)2D3 98 þ 4.2
Muscle cells were treated with 1 nM 1,25(OH)2D3 during 1 min
in the absence or presence of 10 WM PP1. Cell lysates were pre-
cipitated with anti-active MAPK antibody and MAPK activity
of the immunoprecipitate was measured using myelin basic pro-
tein as a substrate as described in Section 2. Control: 160 þ 12
(cpmU1032). Results are the average þ S.D. of three independ-
ent experiments performed in triplicate. *P6 0.005.
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were probed with anti-active MAP kinase antibody
which recognizes the phosphorylated forms of both
the 42 and 44 kDa species. As shown in Fig. 2, under
these conditions the e¡ects of the hormone on
MAPK phosphorylation were abolished. Similar re-
sults were obtained when MAPK activity was mea-
sured, using myelin basic protein as a substrate
(Table 2). Antisense technology allows selective inhi-
bition of the expression of one particular protein
involved in signal transduction and to investigate
how its knockout a¡ects a determined cell function
[54,55]. To answer the question to which extent com-
plete abolition of 1,25(OH)2D3-stimulated MAPK by
c-Src inhibition re£ects an absolute requirement of
c-Src for the hormone-dependent MAPK activation,
we blocked the expression of c-Src by transfecting
cells with an antisense oligodeoxynucleotide against
c-Src mRNA from G. gallus. As observed in Fig. 3,
in cells transfected with the c-Src antisense ODN
the phosphorylation of MAP kinase induced by
1,25(OH)2D3 was reduced up to 90% with respect
to the control; however, the control c-Src sense
ODN was not able to modify the magnitude of the
hormone-dependent MAPK phosphorylation. More-
over, immunoblotting of cell lysates with anti-c-Src
antibody proved the ability of the antisense ODN to
suppress the targeted c-Src protein whereas no
changes were detected in cells transfected with the
sense ODN (data not given). Thus, the data from
the above described set of experiments provide
strong evidence indicating that activation of c-Src is
Fig. 2. c-Src inhibitor PP1 blocks activation of MAP kinase by
1,25(OH)2D3 in muscle cells. Chick skeletal muscle cells were
treated with 1 nM 1,25(OH)2D3 for 1 min in the absence or
presence of the speci¢c c-Src inhibitor PP1 (10 WM). After cell
lysis, comparable aliquots of lysate proteins were separated by
SDS^PAGE followed by Western blotting with anti-active
MAPK as described in Section 2. (A) Representative immuno-
blot. (B) Quanti¢cation by scanning volumetric densitometry of
blots from three independent experiments; averages þ S.D. are
given. **P6 0.01 with respect to the control without (3) PP1.
(C) The blotted membrane shown in panel A was re-probed
with anti-ERK1/2 antibody as indicated in Section 2 in order
to evaluate equivalence of MAPK kinase content among the
di¡erent experimental conditions.
Fig. 3. E¡ect of an antisense oligodeoxynucleotide against c-Src
mRNA on 1,25(OH)2D3-induced MAP kinase phosphorylation.
Chick skeletal muscle cells were transfected with either a sense
(ODN-S) or an antisense (ODN-AS) oligodeoxynucleotide
against c-Src mRNA, and 48 h later the cells were exposed to
1 nM 1,25(OH)2D3 during 1 min followed by immunoblotting
of cell lysates with anti-active MAPK as described in Section 2.
(A) Representative immunoblot. (B) Quanti¢cation by scanning
volumetric densitometry of blots from two independent experi-
ments; averages þ S.D. are given. *P6 0.05, **P6 0.01, with re-
spect to the corresponding control.
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part of the mechanism through which 1,25(OH)2D3
stimulates MAPK in avian skeletal muscle cells.
Upon activation by various extracellular stimuli,
MAP kinase translocates to the nucleus where it
can activate (by phosphorylation) or induce the ex-
pression of transcription factors involved in DNA
synthesis and cell division [45]. To investigate
whether 1,25(OH)2D3 operates through a similar
mechanism, muscle cells were stimulated with the
hormone (1 nM) for 3^15 min followed by isolation
of nuclei. Immunoblot analysis with anti-active
MAPK antibody showed that 1,25(OH)2D3 signi¢-
cantly increased the amounts of MAPK in the nu-
clear fraction between 3 and 10 min, with highest
stimulation reached at 5 min (Fig. 4). These results
indicate that after hormone exposure MAPK is
translocated to the nucleus in the active, phosphory-
lated form. Lower levels of MAPK than basal were
detected after 15 min treatment with 1,25(OH)2D3,
which may be tentatively attributed to hormone-de-
pendent activation of tyrosine phosphatases.
It has been shown previously that the proliferative
e¡ects of 1,25(OH)2D3 in muscle cells [33] and HL-
60 promyelocytic leukaemia cells [56] are accompa-
nied by enhanced mRNA levels of the nuclear proto-
oncoprotein c-myc known to induce the expression
of genes involved in cell growth stimulation. There-
fore, we then investigated the possibility that
1,25(OH)2D3 upregulates the synthesis of the c-myc
oncoprotein through the MAP kinase pathway. To
that end, muscle cells were treated for 18 h with 1 nM
1,25(OH)2D3 (concentration with leads to maximal
activation of the MAPK cascade in these cells [31])
in the presence or absence of PD98059 (10 WM),
which inhibits MAPK activation by the dual
MAPK kinase MEK. Cell lysates were immunopre-
cipitated followed by immunoblotting with a highly
speci¢c anti-c-myc monoclonal antibody. As shown
in Fig. 5, the expression of c-myc, which appeared as
a band of 65 kDa, was increased by 1,25(OH)2D3
almost 1-fold (+90%; P6 0.01) with respect to basal
Fig. 4. Time course of nuclear translocation of MAP kinase ac-
tivated by 1,25(OH)2D3. Muscle cells were treated with 1 nM
1,25(OH)2D3 during 3^15 min. The nuclei were isolated and
Western blot of nuclear proteins with anti-active MAPK was
performed as described in Section 2. (A) Representative immu-
noblot. (B) Quanti¢cation by scanning volumetric densitometry
of blots from three independent experiments; averages þ S.D.
are given. *P6 0.05 with respect to 0 min.
Fig. 5. 1,25(OH)2D3-induced c-myc protein expression is sup-
pressed by MAP kinase inhibitor PD98059. Muscle cells were
treated for 18 h with 1 nM 1,25(OH)2D3 in the absence or
presence of PD98059 (10 WM). Cell lysates were both immuno-
precipitated and then immunoblotted with anti-c-myc antibody
as described in Section 2. (A) Representative immunoblot.
(B) Quanti¢cation by scanning volumetric densitometry of blots
from three independent experiments; averages þ S.D. are given.
**P6 0.01 for 1,25(OH)2D3 vs. control; *P6 0.05 for
1,25(OH)2D3+PD98059 vs. PD98059.
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levels. However, when myoblasts were incubated
with 1,25(OH)2D3 in the presence of PD98059 the
hormone response was markedly reduced (+23%
with respect to PD98059 alone; P6 0.05). Cells
treated with PD98059 in the absence of metabolite
showed a small increase (+18%) in c-myc levels
which was not statistically signi¢cant. These results
indicate that the MAPK cascade contributes to a
great extent to 1,25(OH)2D3 signalling pathways reg-
ulating c-myc synthesis.
There is evidence showing that c-myc function
may be regulated by phosphorylation [57,58]. The
N-terminal domain of the c-myc protein has been
reported to be critical for both transactivation and
the biological function of the c-myc protein. The
oncoprotein is phosphorylated at multiple sites in
vivo, two of which have been identi¢ed near the ami-
no terminus [59]. We have recently reported that
1,25(OH)2D3 stimulates tyrosine phosphorylation of
c-myc [31]. To evaluate if c-Src kinase is involved in
1,25(OH)2D3-induced c-myc phosphorylation, we
pretreated muscle cells with the c-Src inhibitor PP1
(10 WM). Cell lysates were then immunoprecipitated
with the anti-c-myc monoclonal antibody followed
by Western blotting with anti-phosphotyrosine anti-
body. Fig. 6 shows that pretreatment of muscle cells
with PP1 suppressed hormone-dependent tyrosine
phosphorylation of c-myc. Moreover, in cells trans-
fected with the c-Src antisense ODN the phosphory-
lation of c-myc induced by 1,25(OH)2D3 was com-
pletely abolished (unpublished observations).
In conclusion, the results generated in the present
study demonstrate that 1,25(OH)2D3 stimulates cell
proliferation signalling pathways related to MAP ki-
nase and the oncoprotein c-myc in skeletal muscle
and implicate c-Src kinase as mediator of this re-
sponse. Activation of the Ca2 messenger system in
turn appears to play a primary role in triggering the
increase in c-Src. As shown before, the transduction
pathway events which occur between initiation of the
1,25(OH)2D3 signal and the elevation of muscle in-
tracellular Ca2 include PKA- and PKC-dependent
stimulation of VDCC, PLC-mediated Ca2 mobiliza-
tion from inner stores and activation of SOC chan-
nels via PKC and calmodulin [23,60]. The new infor-
mation here provided expands existing knowledge on
the mechanism underlying modulation of muscle cel-
lular growth by 1,25(OH)2D3 [31^33].
Acknowledgements
This research was supported by grants from the
Consejo Nacional de Investigaciones Cienti¢cas y
Te¤cnicas (CONICET), Agencia Nacional de Promo-
cio¤n Cient|¤¢ca y Tecnolo¤gica, Comisio¤n de Investi-
gaciones Cient|¤¢cas de la Provincia de Buenos Aires
(CIC) and Universidad Nacional del Sur, Argentina.
References
[1] H. Reichel, H.P. Koe¥er, A.W. Norman, New Engl. J. Med.
320 (1989) 980^991.
[2] M.R. Walters, Endocr. Rev. 13 (1992) 719^764.
[3] H.P. Koe¥er, Haematol. Blood Transfus. 29 (1985) 409^
417.
[4] R.K. Wali, M. Bissonette, K. Jiang, S.M. Niedziela, S.
Khare, H.K. Roy, M.D. Sitrin, T.A. Brasitus, J. Cell. Phys-
iol. 162 (1995) 172^180.
Fig. 6. c-Src inhibitor PP1 blocks 1,25(OH)2D3-dependent c-
myc tyrosine phosphorylation. Muscle cells were exposed for
1 min to 1 nM 1,25(OH)2D3 in the absence or presence of PP1
(10 WM). The cells were then lysed, immunoprecipitated with
anti-c-myc antibody followed by immunoblotting with anti-
phosphotyrosine antibody. (A) Representative immunoblot.
(B) Quanti¢cation by scanning densitometry of blots from three
independent experiments; averages þ S.D. are given. **P6 0.01.
BBAMCR 14795 7-12-01
C. Buitrago et al. / Biochimica et Biophysica Acta 1541 (2001) 179^187186
[5] H.F. DeLuca, K. Heinrich, A. Schnoes, Annu. Rev. Bio-
chem. 52 (1983) 411^439.
[6] P.P. Minghetti, A.W. Norman, FASEB J. 2 (1988) 3043^
3053.
[7] I. Nemere, Y. Yoshimoto, A.W. Norman, Endocrinology
115 (1984) 1476^1483.
[8] M.J. Lieberherr, J. Biol. Chem. 262 (1987) 13168^13173.
[9] R.K. Wali, C.L. Baum, M.D. Sitrin, M.J.G. Bolt, P.K. Du-
deja, T.A. Brasitus, Am. J. Physiol. 262 (1992) G945^G953.
[10] A.R. de Boland, I. Nemere, J. Cell. Biochem. 49 (1992) 32^
36.
[11] D.T. Baran, A.M. Sorensen, V. Shalhoub, T. Owen, A.
Oberdof, G. Stein, J. Lian, J. Bone Miner. Res. 6 (1991)
1269^1275.
[12] A.R. de Boland, R. Boland, Cell. Signal. 6 (1994) 717^724.
[13] D.T. Baran, J. Cell. Biochem. 56 (1994) 303^306.
[14] I. Nemere, M.C. Dormanen, M.W. Hammond, W.H. Oka-
mura, A.W. Norman, J. Biol. Chem. 269 (1994) 23750^
23756.
[15] I. Nemere, Z. Schwartz, H. Pedrozo, V.L. Sylvia, D.D.
Dean, B.D. Boyan, J. Bone Miner. Res. 13 (1998) 1353^
1359.
[16] S. Morelli, A.R. de Boland, R. Boland, Biochem. J. 289
(1993) 675^679.
[17] A.R. de Boland, S. Morelli, R. Boland, J. Biol. Chem. 269
(1994) 8675^8679.
[18] A.R. de Boland, S. Morelli, R. Boland, Biochim. Biophys.
Acta 1257 (1995) 274^278.
[19] G. Vazquez, A.R. de Boland, Biochim. Biophys. Acta 1310
(1996) 157^162.
[20] S. Morelli, R. Boland, A.R. de Boland, Mol. Cell. Endocri-
nol. 122 (1996) 207^211.
[21] G. Vazquez, A.R. de Boland, R. Boland, Biochem. Biophys.
Res. Commun. 234 (1997) 125^128.
[22] G. Vazquez, A.R. de Boland, R. Boland, Biochem. Biophys.
Res. Commun. 239 (1997) 562^565.
[23] G. Vazquez, A.R. de Boland, R. Boland, J. Biol. Chem. 273
(1998) 33954^33960.
[24] C. Buitrago, G. Vazquez, A. De Boland, R. Boland, J. Cell.
Biochem. 79 (2000) 274^281.
[25] S. Khare, M.J.G. Bolt, R.K. Wali, S.F. Skarosi, H.K. Roy,
S. Niedziela, B. Scaglione-Sewell, B. Aquino, C. Abraham,
M.D. Sitrin, T.A. Brasitus, M. Bissonette, J. Clin. Invest. 99
(1997) 1831^1841.
[26] R. Gniadecki, Biochem. Pharmacol. 55 (1998) 499^503.
[27] L.M. Luttrell, B.E. Hawes, T. Van Biesen, D.K. Luttrell,
T.J. Lansing, R.J. Lefkowitz, J. Biol. Chem. 271 (1996)
19443^19450.
[28] Y. Wan, T. Kurosaki, X.Y. Huang, Nature 380 (1996) 541^
545.
[29] X. Song, J.E. Bishop, W.H. Okamura, A.W. Norman, En-
docrinology 139 (1998) 457^465.
[30] A.R. de Boland, A.W. Norman, J. Cell. Biochem. 69 (1998)
470^482.
[31] S. Morelli, C. Buitrago, G. Vazquez, A.R. de Boland, R.
Boland, J. Biol. Chem. 275 (2000) 36021^36028.
[32] R.J. Gniadecki, Invest. Dermatol. 106 (1998) 1212^1217.
[33] L. Drittanti, A.R. de Boland, R. Boland, Biochim. Biophys.
Acta 1014 (1989) 112^119.
[34] T. Bellido, S. Morelli, L.M. Fernandez, R. Boland, Mol.
Cell. Endocrinol. 90 (1993) 231^238.
[35] R. Boland, A.R. de Boland, M. Marinissen, G. Santillan, G.
Vazquez, S. Zanello, Mol. Cell. Endocrinol. 114 (1995) 1^8.
[36] G. Vazquez, A.R. de Boland, Biochem. Mol. Biol. Int. 31
(1993) 677^684.
[37] D.A. Capiati, F. Limbozzi, M.T. Te¤llez-In‹o¤n, R. Boland,
J. Cell. Biochem. 74 (1999) 292^300.
[38] P. Cohen, M.A. Rosemeyer, Eur. J. Biochem. 8 (1969) 1^7.
[39] O.H. Lowry, N.J. Rosebrough, A.L. Farr, R.J. Randall,
J. Biol. Chem. 195 (1951) 265^277.
[40] U.K. Laemmli, Nature 227 (1970) 680^685.
[41] D.A. Capiati, G. Vazquez, M.T. Tellez-In‹on, R.L. Boland,
Cell Prolif. 33 (2000) 307^315.
[42] D.A. Capiati, G. Vazquez, R.L. Boland, Horm. Metab. Res.
(2001) in press.
[43] G. Snedecor, W. Cochran, Statistical Methods, Iowa State
University Press, Ames, IA, 1967.
[44] T. Erpel, S.A. Courtneidge, Curr. Opin. Cell Biol. 7 (1995)
176^182.
[45] C.J. Marshall, Cell 80 (1995) 179^185.
[46] G. Vazquez, J. Selles, A.R. De Boland, R. Boland, Br. J.
Pharmacol. 126 (1999) 1815^1823.
[47] D. Capiati, G. Vazquez, R. Boland, Horm. Metab. Res.
(2001) in press.
[48] H. Piwnica-Worms, K.B. Saunders, T.M. Roberts, A.E.
Smith, S.H. Cheng, Cell 49 (1987) 75^82.
[49] M.T. Brown, J.A. Cooper, Biochim. Biophys. Acta 1287
(1996) 121^149.
[50] Y. Tsunoda, H. Yoshida, L. Africa, G.J. Steil, C. Owyang,
Biochem. Biophys. Res. Commun. 227 (1996) 876^884.
[51] M.S. Simonson, Y. Wang, W.H. Hernan, Am. J. Physiol.
270 (1996) F790^F797.
[52] N.G. Anderson, J.L. Maller, N.K. Tonks, T.W. Sturgiel,
Nature 343 (1990) 651^653.
[53] J.H. Hanke, J.P. Gardner, R.L. Dow, P.S. Changelian, W.H.
Brissette, E.J. Weringer, A. Pollock, P.A. Connelly, J. Biol.
Chem. 271 (1996) 695^701.
[54] C. Kleuss, J. Hescheler, C. Ewel, W. Rosenthal, G. Schultz,
B. Wittig, Nature 353 (1991) 43^48.
[55] F. Kalkbrenner, V.E. Degtiar, M. Schenker, S. Brendel, A.
Zobel, J. Hescheler, B. Wittig, G. Schultz, EMBO J. 14
(1995) 4728^4737.
[56] R.U. Simpson, T. Hsu, D.A. Begley, B.S. Mitchell, B.N.
Alizadeh, J. Biol. Chem. 262 (1987) 4104^4108.
[57] A. Seth, E. Alvarez, S. Gupta, R.J. Davis, J. Biol. Chem. 266
(1991) 23521^23524.
[58] M. Henriksson, A. Bakardjiev, G. Klein, B. Luscher, Onco-
gene 12 (1993) 3199^3209.
[59] B. Lutterbach, S.R. Hann, Mol. Cell. Biol. 14 (1994) 5510^
5522.
[60] G. Vazquez, A.R. De Boland, R. Boland, J. Biol. Chem. 275
(2000) 16134^16138.
BBAMCR 14795 7-12-01
C. Buitrago et al. / Biochimica et Biophysica Acta 1541 (2001) 179^187 187
